SCHEMBL14745954

SCHEMBL14745954

CCCC(=O)c1ccc2c(ccn2C)c1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
CYP2C19 P33261 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP3A4 P08684 1/20 0.39
SRD5A2 P31213 1/20 0.38
EGFR P00533 3/20 0.37
HPGD P15428 2/20 0.37
MAOB P27338 1/20 0.37
PDE4D Q08499 1/20 0.37
BRD4 O60885 1/20 0.36
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
SENP5 Q96HI0 1/20 0.36
SENP2 Q9HC62 1/20 0.36
SENP1 Q9P0U3 1/20 0.36
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNE1 P24864 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744993 0.84 LMNA (0.49) LMNAL3MBTL1SRD5A2HPGDBRD4
SCHEMBL14758005 0.83 THRB (0.39) LMNAL3MBTL1CYP3A4PDE4DTHRA
SCHEMBL14745011 0.81 TSHR (0.33) CYP2C19L3MBTL1CYP3A4SRD5A2HPGD
SCHEMBL14745010 0.81 TSHR (0.33) CYP2C19L3MBTL1CYP3A4SRD5A2HPGD
SCHEMBL8913156 0.77 MEN1 (0.42) LMNAL3MBTL1HPGDBRD4SMN1; SMN2
SCHEMBL28151566 0.77 MEN1 (0.42) L3MBTL1SRD5A2HPGDMAOBBRD4
SCHEMBL9315204 0.76 HTR1A (0.43) LMNAL3MBTL1HPGDTHRBSMN1; SMN2
SCHEMBL14745549 0.76 KDM4E (0.38) L3MBTL1SRD5A2HPGDBRD4SMN1; SMN2
SCHEMBL14744889 0.75 MAPT (0.37) LMNASRD5A2HPGDBRD4THRB
SCHEMBL14745052 0.75 NPC1 (0.44) L3MBTL1HPGDMAOBBRD4CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP LMNA 2119/4885CYP2C19 4136/4885L3MBTL1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.